Brad Martin is Head of Market Access at Neurotech, bringing more than 20 years of leadership experience in the biopharmaceutical industry.
He has led commercial strategy and execution across multiple therapeutic areas, including Cell and Gene Therapy, CNS, Rare Diseases, and Ophthalmology.
His career includes senior roles at GlaxoSmithKline, UCB, ISTA Vision, Lundbeck, AveXis/Novartis Gene Therapies, Sarepta Therapeutics, and Taysha Gene Therapies. Brad has successfully led market access and distribution strategies from pre-commercial planning through product launch, engaging with payers, specialty pharmacies, and healthcare systems.
He serves on advisory boards with Cencora Cell and Gene and MIT’s New Digs pricing consortium. Brad holds a Bachelor of Science from Northeastern University.
